Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $19.52

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned an average rating of “Hold” from the twenty-one brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $20.0455.

Several research analysts have issued reports on NTLA shares. Canaccord Genuity Group dropped their price objective on Intellia Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a report on Monday, March 2nd. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Truist Financial upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Chardan Capital upped their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of NTLA. Farallon Capital Management LLC acquired a new stake in shares of Intellia Therapeutics in the third quarter valued at $10,486,000. SG Americas Securities LLC lifted its position in Intellia Therapeutics by 239.7% during the 3rd quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock worth $2,264,000 after buying an additional 92,485 shares in the last quarter. Vanguard Group Inc. lifted its position in Intellia Therapeutics by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock worth $190,744,000 after buying an additional 192,651 shares in the last quarter. Jupiter Asset Management Ltd. bought a new stake in Intellia Therapeutics during the 3rd quarter worth about $23,519,000. Finally, Contrarius Group Holdings Ltd grew its holdings in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after acquiring an additional 4,337,428 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Down 4.5%

NASDAQ NTLA opened at $13.01 on Friday. Intellia Therapeutics has a 1-year low of $6.83 and a 1-year high of $28.25. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -3.40 and a beta of 1.99. The stock’s 50 day moving average is $13.59 and its two-hundred day moving average is $12.89.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The business had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.Intellia Therapeutics’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.27) EPS. On average, analysts predict that Intellia Therapeutics will post -3.53 earnings per share for the current year.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Intellia reported positive topline Phase 3 HAELO results for lonvoguran (ziclumeran) that met the primary and all key secondary endpoints and showed favorable safety — a potential first-ever one-time in‑vivo gene‑editing therapy for HAE, a major clinical milestone. Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema
• Positive Sentiment: Intellia initiated a rolling BLA submission to the FDA for lonvo‑z and provided a first‑half‑2027 U.S. launch expectation if approved — a clear path to commercialization that materially derisks program timing. Intellia Initiates Rolling Submission of BLA to FDA for Lonvoguran
• Positive Sentiment: Major media and wire coverage (Reuters, CNBC) highlighted the Phase 3 success as a landmark for in‑vivo CRISPR therapy, boosting investor interest and helping premarket rallies. Reuters: Intellia therapy meets main goal in trial
• Positive Sentiment: Analyst support and call buying: Chardan raised its price target to $30 (buy) and there was unusual call activity (nearly double typical call volume), signaling bullish speculation around the program. Benzinga / The Fly: Price target and options
• Neutral Sentiment: Robert W. Baird raised its target to $13 and kept a neutral rating — this is a mild endorsement but less bullish than Chardan’s view, reflecting some investor caution on commercialization and valuation. Benzinga: Baird raises target
• Neutral Sentiment: Coverage pieces noting “why shares aren’t flying” provide context: investors are weighing one‑time curative potential against commercial, regulatory and manufacturing unknowns — explains a muted or mixed price response despite big clinical news. MSN: Why shares aren’t flying
• Negative Sentiment: Intellia announced a $150M underwritten public offering (plus a 15% overallotment option). New share issuance is dilutive and often puts short‑term pressure on the stock despite positive clinical news. GlobeNewswire: Proposed public offering
• Negative Sentiment: Despite the favorable trial, several outlets reported intraday selling/stock declines — likely profit‑taking, dilution worries from the offering, and investors locking gains after a big premarket pop. Investing.com: Stock falls despite positive results

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.